Published July 2009 | Version v1
Journal article

Development of a new multi-modal Monte-Carlo radiotherapy planning system

  • 1. Graduate School of Comprehensive Human Science, University of Tsukuba, Tsukuba, Ibaraki (Japan)
  • 2. Department of Research Reactor and Tandem Accelerator, Japan Atomic Energy Agency, Tokai, Ibaraki (Japan)
  • 3. Graduate School of Science and Engineering, Ibaraki University, Mito, Ibaraki (Japan)

Description

A new multi-modal Monte-Carlo radiotherapy planning system (developing code: JCDS-FX) is under development at Japan Atomic Energy Agency. This system builds on fundamental technologies of JCDS applied to actual boron neutron capture therapy (BNCT) trials in JRR-4. One of features of the JCDS-FX is that PHITS has been applied to particle transport calculation. PHITS is a multi-purpose particle Monte-Carlo transport code. Hence application of PHITS enables to evaluate total doses given to a patient by a combined modality therapy. Moreover, JCDS-FX with PHITS can be used for the study of accelerator based BNCT. To verify calculation accuracy of the JCDS-FX, dose evaluations for neutron irradiation of a cylindrical water phantom and for an actual clinical trial were performed, then the results were compared with calculations by JCDS with MCNP. The verification results demonstrated that JCDS-FX is applicable to BNCT treatment planning in practical use.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.apradiso.2009.03.028

Additional details

Identifiers

DOI
10.1016/j.apradiso.2009.03.028;
PII
S0969-8043(09)00262-0;

Publishing Information

Journal Title
Applied Radiation and Isotopes
Journal Volume
67
Journal Issue
7-8,suppl
Journal Page Range
p. S118-S121
ISSN
0969-8043
CODEN
ARISEF

Conference

Title
A new option against cancer
Acronym
13. international congress on neutron capture therapy BNCT
Dates
2-8 Nov 2008
Place
Florence (Italy)

Optional Information

Copyright
Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.